Edward Nash
Stock Analyst at Canaccord Genuity
(4.90)
# 273
Out of 5,040 analysts
384
Total ratings
50.4%
Success rate
27.4%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRAX First Tracks Biotherapeutics | Reiterated: Buy | $50 | $32.01 | +56.20% | 2 | Oct 9, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $114 | $27.73 | +311.11% | 11 | Oct 7, 2026 | |
| CNTB Connect Biopharma Holdings | Reiterated: Buy | $6 | $0.8807 | +581.28% | 6 | Oct 1, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $56 | $8.92 | +527.80% | 13 | Oct 1, 2026 | |
| IVA Inventiva | Reiterated: Buy | $20 → $21 | $3.32 | +532.53% | 15 | Sep 29, 2026 | |
| NKTR Nektar Therapeutics | Reiterated: Buy | $153 | $40.80 | +275.00% | 4 | Sep 28, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $60 | $29.30 | +104.78% | 14 | Sep 23, 2026 | |
| TSX: CRDL Cardiol Therapeutics Inc. | Reiterated: Buy | $14.25 | $1.85 | +670.19% | 27 | Sep 23, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $111 | $25.67 | +332.41% | 4 | Sep 9, 2026 | |
| ACRS Aclaris Therapeutics | Initiated Coverage: Buy | $10 | $3.79 | +163.85% | 1 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.792 | +531.31% | 20 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $161 | $118.54 | +35.82% | 56 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $1.00 | +200.00% | 16 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $98 | $78.75 | +24.44% | 5 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $587 → $612 | $476.91 | +28.33% | 42 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $52.04 | +34.51% | 41 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $129 | $109.30 | +18.02% | 5 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 | $2.42 | +933.06% | 3 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $4.64 | n/a | 8 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $4.20 | n/a | 6 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $1 | $0.0001 | n/a | 2 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $8.17 | n/a | 2 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 | $1.53 | n/a | 1 | Jun 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 → $39 | $3.47 | n/a | 9 | May 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $176 | $18.21 | n/a | 15 | Feb 27, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $64 | $22.54 | n/a | 2 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $126 → $117 | $54.89 | n/a | 14 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $54 → $71 | $15.29 | n/a | 11 | Jan 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $156 | $46.21 | n/a | 1 | Sep 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $132 | $818.63 | n/a | 1 | Sep 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 → $4 | $17.17 | n/a | 3 | Jun 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $15.18 | n/a | 1 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $23 | $4.96 | n/a | 2 | May 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $0.0001 | n/a | 1 | Sep 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $2 | $0.000135 | n/a | 2 | May 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $6 | $2.70 | n/a | 8 | May 5, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $7.56 | n/a | 3 | Mar 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 → $11 | $3.87 | n/a | 3 | Sep 4, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $0.1401 | n/a | 1 | Jun 17, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $15.04 | n/a | 2 | May 3, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $19.58 | n/a | 1 | Jan 28, 2013 |
First Tracks Biotherapeutics
Oct 9, 2026
Reiterated: Buy
Price Target: $50
Current: $32.01
Upside: +56.20%
Viking Therapeutics
Oct 7, 2026
Reiterated: Buy
Price Target: $114
Current: $27.73
Upside: +311.11%
Connect Biopharma Holdings
Oct 1, 2026
Reiterated: Buy
Price Target: $6
Current: $0.8807
Upside: +581.28%
Sagimet Biosciences
Oct 1, 2026
Reiterated: Buy
Price Target: $56
Current: $8.92
Upside: +527.80%
Inventiva
Sep 29, 2026
Reiterated: Buy
Price Target: $20 → $21
Current: $3.32
Upside: +532.53%
Nektar Therapeutics
Sep 28, 2026
Reiterated: Buy
Price Target: $153
Current: $40.80
Upside: +275.00%
Celldex Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $60
Current: $29.30
Upside: +104.78%
Cardiol Therapeutics Inc.
Sep 23, 2026
Reiterated: Buy
Price Target: $14.25
Current: $1.85
Upside: +670.19%
Structure Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $111
Current: $25.67
Upside: +332.41%
Aclaris Therapeutics
Sep 1, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $3.79
Upside: +163.85%
Aug 17, 2026
Reiterated: Buy
Price Target: $5
Current: $0.792
Upside: +531.31%
Aug 13, 2026
Reiterated: Buy
Price Target: $161
Current: $118.54
Upside: +35.82%
Aug 13, 2026
Reiterated: Hold
Price Target: $3
Current: $1.00
Upside: +200.00%
Aug 12, 2026
Reiterated: Buy
Price Target: $98
Current: $78.75
Upside: +24.44%
Aug 11, 2026
Reiterated: Buy
Price Target: $587 → $612
Current: $476.91
Upside: +28.33%
Aug 11, 2026
Reiterated: Buy
Price Target: $70
Current: $52.04
Upside: +34.51%
Aug 6, 2026
Reiterated: Buy
Price Target: $129
Current: $109.30
Upside: +18.02%
May 14, 2026
Rated: Buy
Price Target: $25
Current: $2.42
Upside: +933.06%
Oct 2, 2024
Reiterated: Buy
Price Target: $9
Current: $4.64
Upside: n/a
May 17, 2023
Reiterated: Hold
Price Target: $2
Current: $4.20
Upside: n/a
Jul 29, 2022
Downgraded: Hold
Price Target: $12 → $1
Current: $0.0001
Upside: n/a
May 18, 2021
Reiterated: Buy
Price Target: $25
Current: $8.17
Upside: n/a
Jun 5, 2019
Downgraded: Hold
Price Target: $5
Current: $1.53
Upside: n/a
May 20, 2019
Reiterated: Buy
Price Target: $60 → $39
Current: $3.47
Upside: n/a
Feb 27, 2019
Reiterated: Buy
Price Target: $176
Current: $18.21
Upside: n/a
Feb 26, 2019
Reiterated: Buy
Price Target: $48 → $64
Current: $22.54
Upside: n/a
Feb 25, 2019
Reiterated: Buy
Price Target: $126 → $117
Current: $54.89
Upside: n/a
Jan 23, 2019
Reiterated: Buy
Price Target: $54 → $71
Current: $15.29
Upside: n/a
Sep 24, 2018
Reiterated: Buy
Price Target: $156
Current: $46.21
Upside: n/a
Sep 17, 2018
Reiterated: Buy
Price Target: $132
Current: $818.63
Upside: n/a
Jun 27, 2018
Downgraded: Hold
Price Target: $22 → $4
Current: $17.17
Upside: n/a
Jun 25, 2018
Initiated Coverage: Buy
Price Target: $26
Current: $15.18
Upside: n/a
May 16, 2018
Reiterated: Buy
Price Target: $26 → $23
Current: $4.96
Upside: n/a
Sep 18, 2017
Reiterated: Buy
Price Target: $24
Current: $0.0001
Upside: n/a
May 16, 2017
Reiterated: Hold
Price Target: $1 → $2
Current: $0.000135
Upside: n/a
May 5, 2017
Reiterated: Hold
Price Target: $3 → $6
Current: $2.70
Upside: n/a
Mar 7, 2017
Reiterated: Hold
Price Target: $9
Current: $7.56
Upside: n/a
Sep 4, 2014
Downgraded: Hold
Price Target: $14 → $11
Current: $3.87
Upside: n/a
Jun 17, 2013
Initiated Coverage: Buy
Price Target: n/a
Current: $0.1401
Upside: n/a
May 3, 2013
Downgraded: Sell
Price Target: n/a
Current: $15.04
Upside: n/a
Jan 28, 2013
Initiated Coverage: Buy
Price Target: n/a
Current: $19.58
Upside: n/a